An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old — MACS2163

ß-thalassemia Major Clinical Trial

Official title:
An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old

Status Withdrawn

Clinical Trial Summary

To characterize the PK of deferasirox in pediatric β-thalassemia major patients aged from 2 to less than 6 years old, when administrated with a fixed starting dose of 20 mg/kg/day.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01724138
Study type	Interventional
Source	Novartis
Contact
Status	Withdrawn
Phase	Phase 4
Start date	June 2013
Completion date	October 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00390858` - A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.	Phase 2
Active, not recruiting	`NCT01846923` - B Memory Cell Response to Vaccination With the 13-valent Pneumococcal Conjugate Vaccine in Asplenic Individuals	Phase 4
Terminated	`NCT04205435` - β-globin Restored Autologous HSC in β-thalassemia Major Patients	Phase 1/Phase 2
Not yet recruiting	`NCT04592458` - Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients	Phase 1
Completed	`NCT01745120` - A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants	Phase 1/Phase 2